Baird analyst Catherine Schulte lowered the firm’s price target on Bio-Techne to $90 from $100 and keeps an Outperform rating on the shares. The firm said they reported mixed 4Q results, with organic revenue growth below expectations largely due to China, but earnings per share were in line with Street.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TECH:
- Bio-Techne reports Q4 adjusted EPS 55c, consensus 55c
- BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2023 RESULTS
- BIO-TECHNE DECLARES DIVIDEND
- Bio-Techne (TECH) Q4 Earnings Cheat Sheet
- Maravai attracted takeover interest from Bio-Techne, Street Insider says
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue